Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Ginkgo Bioworks Q4 2025 Earnings Call - Ginkgo doubles down on autonomous labs, spins off biosecurity
Ginkgo used the quarter to draw a hard line in the sand. Management will pivot the company into the autonomous lab category as its core strategy for 2026, reallocating capital and operational focus to...
- CEO Jason Kelly announced an explicit strategic pivot: 2026 will focus on winning the autonomous lab category, reallocating capital and attention away from other initiatives.
- Ginkgo will divest its biosecurity business into a private entity, keeping a minority stake, to free up capital and bring defense-focused investors into that business.
- Management plans to systematically decommission traditional benches and work cells, migrating internal R&D onto a single large autonomous lab in Boston called Nebula as a commercial proof point.
- +12 more takeaways
Natera Q4 2025 Earnings Call - MRD volume surge and margin breakout set stage for $2.62–2.7B 2026 guide
Natera closed 2025 with a blowout quarter, driven by MRD adoption and operational gains. The company processed about 924,000 tests in Q4, including a record 225,000 MRD clinical units, producing $666 ...
- Q4 volume and revenue outperformed: ~924,000 tests processed, $666M revenue, about $6M ahead of the January pre-announce, roughly 40% revenue growth year-over-year.
- MRD momentum is the engine: 225,000 MRD clinical units in Q4, up about 56% versus Q4 2024; management estimates over 50% of US oncologists ordered a Signatera test in the quarter.
- Gross margin expansion was material: reported margin 66.9% in Q4, with organic gross margin 63.7% after stripping ~$60M of revenue true-ups; management sees additional margin upside in 2026.
- +16 more takeaways
Organogenesis Holdings, Inc. Q4 2025 Earnings Call - Record Q4 revenue, but CMS December commentary sparks near-term utilization shock and 2026 revenue guidance cut
Organogenesis closed 2025 with a blowout quarter, reporting $225.1 million of net product revenue in Q4, driven by an 83% year-over-year surge in advanced wound care and materially better margins. Man...
- Q4 2025 net product revenue $225.1 million, up 78% year-over-year and 50% sequentially, beating prior guidance by a wide margin.
- Advanced wound care sales jumped 83% year-over-year in Q4 and were the primary driver of the record quarter.
- Surgical and Sports Medicine sales were down 2% in Q4 but up 12% for full-year 2025, led by PuraPly growth.
- +13 more takeaways
Cytek Biosciences Q4 2025 Earnings Call - Return to growth led by recurring revenue and APAC momentum, but profitability pressured by a large tax valuation allowance and higher operating costs
Cytek closed 2025 with accelerating top-line momentum, reporting Q4 revenue of $62.1 million, up 8% year-over-year, and full-year revenue of $201.5 million, up 1%. Growth was broad-based by region in ...
- Q4 revenue $62.1M, +8% year-over-year; full-year 2025 revenue $201.5M, +1% year-over-year.
- Installed base reached 3,664 units after adding 208 instruments in Q4; 2025 unit order volume rose 22% year-over-year and accelerated to 26% in Q4.
- Recurring revenue now 34% of total and grew 21% year-over-year, driven by service, reagents, and cloud adoption.
- +12 more takeaways
Asure Software Q4 2025 Earnings Call - Asure Central and Luna AI set the stage for a 2026 revenue inflection
Asure closed 2025 with clear top-line momentum and cleaner margins, driven by the rollout of Asure Central and rapid adoption of its Luna AI agent. Full-year revenue reached $140.5 million, up 17% yea...
- Full-year 2025 revenue was $140.5 million, up 17% year over year; Q4 revenue was $39.3 million, up 28% year over year.
- Recurring revenue for 2025 was $127.3 million, an 11% increase year over year; Q4 recurring revenue was $33.7 million, up 18% year over year.
- Organic growth accelerated to 10% in Q4 from 4% in Q3, with full-year organic growth of 5% in 2025.
- +12 more takeaways
Pacira BioSciences Q4 2025 Earnings Call - EXPAREL momentum, IP runway to 2039 and data-rich pipeline set 2026 agenda
Pacira presents a clear reset. FY2025 revenue was $726 million, EXPAREL volumes showed a second-half acceleration and Q4 sales reached $155.8 million, while the company secured a material IP and comme...
- FY2025 revenue was $726 million, with Q4 EXPAREL sales of $155.8 million versus $147.7 million in Q4 2024, reflecting roughly 7% volume growth in the quarter.
- Pacira reported its highest-ever non-GAAP gross margins in Q4, 80% versus 79% a year ago, and guided 2026 non-GAAP gross margins to 77%–79% while targeting a 5 percentage point improvement versus 2024 by 2030 under its 5x30 plan.
- Management says the legal settlement with Fresenius provides EXPAREL volume-limited runway visibility through 2039, and the IP estate has expanded to 21 patents across two families, materially strengthening exclusivity compared with one patent a year ago.
- +12 more takeaways
BioLife Solutions Q4 2025 Earnings Call - BPM dominance fuels 29% FY growth, company guiding to first GAAP profit
BioLife closed 2025 with a clean, narrower portfolio and a clear commercial story. Total revenue from continuing operations rose 29% to $96.2 million, driven by biopreservation media, which made up ab...
- Full-year 2025 revenue from continuing operations was $96.2 million, up 29% year-over-year; Q4 revenue was $24.8 million, up 20% year-over-year.
- Biopreservation media (BPM) accounted for roughly 85% of Q4 revenue and remains the core cash engine for the business.
- Top 20 BPM customers represent about 80% of BPM revenue, concentrating visibility but also client risk.
- +17 more takeaways
Castle Biosciences Fourth Quarter and Full Year 2025 Earnings Call - TissueCypher Momentum and AdvanceAD Early Traction Set the Stage While Margin and Guideline Headwinds Persist
Castle closed 2025 with strong top-line momentum driven by TissueCypher’s 86% volume jump and steady DecisionDx-Melanoma growth, while launching AdvanceAD-Tx into limited access where early clinician ...
- Total revenue for 2025 was $344.2 million, with Q4 revenue of $87.0 million, exceeding guidance.
- TissueCypher test reports jumped 86% in 2025 to 39,014 reports; patient penetration exiting 2025 is roughly 11%, clinician penetration about 25-30% suggesting a large runway.
- DecisionDx-Melanoma delivered 39,083 test reports in 2025, up 9% year-over-year, with patient penetration near 31% and total ordering clinicians approaching 17,000 lifetime.
- +12 more takeaways
Puma Biotechnology Q4 2025 Earnings Call - Nerlynx sales inch up as inventory and China royalty boost results, alisertib trials accelerate
Puma posted a modest quarter where headline revenue gains mask a familiar pattern, inventory builds and a one-time royalty payout did a lot of the heavy lifting. NERLYNX net product revenue rose to $5...
- Total revenue for Q4 2025 was $75.5 million, with NERLYNX net product revenue of $59.9 million and royalty revenue of $15.6 million.
- Q4 NERLYNX product revenue rose versus Q3 2025 ($51.9 million) and Q4 2024 ($54.4 million), driven in part by a $5.7 million inventory build at specialty pharmacies and distributors.
- NERLYNX ex-factory bottle sales were 3,298 in Q4 2025, up roughly 12% quarter-over-quarter and 11% year-over-year; estimated inventory increased by about 343 bottles in Q4.
- +13 more takeaways
OrthoPediatrics Corp. Q4 2025 Earnings Call - Hit first quarterly free cash flow positive, guiding to 2026 FCF breakeven with double-digit growth
OrthoPediatrics closed 2025 with broad-based momentum: Q4 revenue rose 17% to $61.6 million, full-year revenue grew 15%, adjusted EBITDA improved sharply and the company reported its first-ever quarte...
- Q4 2025 revenue $61.6 million, up 17% year-over-year; full-year 2025 revenue up 15%.
- Q4 adjusted EBITDA was $4.8 million, a 59% improvement versus Q4 2024; management says full-year 2025 adjusted EBITDA rose nearly 75% year-over-year.
- Company generated $10 million of free cash flow in Q4, its first quarter of positive FCF in company history; full-year cash usage improved to $15 million from $41 million in 2024.
- +10 more takeaways